PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $82,195,000 | +21.0% | 2,209,599 | -0.1% | 0.07% | +17.5% |
Q4 2016 | $67,922,000 | -55.7% | 2,212,313 | -3.3% | 0.06% | -55.8% |
Q3 2016 | $153,395,000 | +102.7% | 2,287,774 | -9.9% | 0.13% | +101.6% |
Q2 2016 | $75,675,000 | +32.4% | 2,540,331 | +30.6% | 0.06% | +28.0% |
Q1 2016 | $57,141,000 | +24.1% | 1,945,510 | +231.3% | 0.05% | +28.2% |
Q4 2015 | $46,044,000 | -45.7% | 587,302 | -47.8% | 0.04% | +2.6% |
Q3 2015 | $84,804,000 | -8.0% | 1,125,330 | +42.5% | 0.04% | -50.0% |
Q2 2015 | $92,212,000 | -28.9% | 789,824 | +43.8% | 0.08% | -29.0% |
Q1 2015 | $129,660,000 | +78.1% | 549,150 | +42.8% | 0.11% | +72.6% |
Q4 2014 | $72,793,000 | +2.6% | 384,598 | +29.3% | 0.06% | -4.6% |
Q3 2014 | $70,957,000 | +113.5% | 297,425 | -40.9% | 0.06% | +116.7% |
Q2 2014 | $33,238,000 | +5.9% | 503,608 | +67.2% | 0.03% | +3.4% |
Q1 2014 | $31,372,000 | +26.5% | 301,246 | +25.8% | 0.03% | +26.1% |
Q4 2013 | $24,793,000 | – | 239,472 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |